SOZO platform
ImpediMed sells the SOZO bioimpedance system, which measures body fluid changes to help clinicians screen for lymphedema and monitor patients with fluid-related conditions such as heart failure.
Customers and revenue model
ImpediMed Ltd
ASX:IPD
ImpediMed Ltd
ASX:IPD
Price on Oct 14:
0.007
AUD
Market Cap:
AU$25.6m
Prices of ASX stocks are not being updated. The latest IPD price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ImpediMed Ltd
ASX:IPD
|
AU |
|
D
|
Descon Oxychem Ltd
KAR:DOL
|
PK |
|
V
|
Vidaroo Corp
AMEX:VIDA
|
US |
|
H
|
Heimar hf
ICEX:HEIMAR
|
IS |
|
1-800-Flowers.Com Inc
NASDAQ:FLWS
|
US |
|
Brown-Forman Corp
F:BF5B
|
US |
|
Davictus PLC
LSE:DVT
|
MY |
|
G
|
Greattown Holdings Ltd
SSE:900940
|
CN |
|
F
|
Fuel Tech Inc
SWB:FUE1
|
US |
|
N
|
Nextech Ar Solutions Corp
CNSX:NTAR
|
CA |
|
Paramount Global
NASDAQ:PSKY
|
US |
|
R
|
Rapid7 Inc
SWB:R7D
|
US |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Health Care
- Headquarters
- Australia AU
- Employees
- 77
- IPO date
- Oct 24, 2007
ImpediMed Ltd is a medical technology company that makes devices and software for measuring body fluid and tissue composition with bioimpedance spectroscopy. Its best-known product is the SOZO system, which gives clinicians a quick, non-invasive read on fluid changes in patients. The company focuses on turning those measurements into practical tools for early detection and ongoing monitoring, especially in cancer care and heart failure care.
The main customers are hospitals, oncology centers, cardiology practices, and other clinics that monitor patients at risk of fluid-related complications such as lymphedema. ImpediMed sells its systems to healthcare providers and also earns recurring income from software, data, and usage-based services tied to the platform. In simple terms, it makes money by placing its measurement tools into clinical workflows and then charging for the hardware and the ongoing access around it.
What makes ImpediMed different is that it sits at the point where imaging, monitoring, and digital records meet. Instead of being a general medical equipment maker, it focuses on one specific measurement method that can help clinicians spot changes earlier than a physical exam alone. That gives it a niche role in care pathways where repeated, standardized measurements matter more than one-time testing.
Continue IPD Research
Other ImpediMed Ltd listings: